{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:17:42Z","timestamp":1790788662553,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bulcan.2023.01.013","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T08:05:47Z","timestamp":1677744347000},"page":"402-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cibler HER2\u00a0dans le cancer colorectal"],"prefix":"10.1016","volume":"110","author":[{"given":"El\u00e9onore","family":"Spitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2023.01.013_bib0325","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36\u00a0cancers in 185\u00a0countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0330","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36\u00a0cancers in 185\u00a0countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0335","unstructured":"Assessment of a HER2\u00a0scoring system for colorectal cancer: results from a validation study \u2013 PubMed [Internet]. [cited 2022\u00a0Jun 3]. Disponible \u00e0\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/26449765\/."},{"key":"10.1016\/j.bulcan.2023.01.013_bib0340","unstructured":"Human epidermal growth factor receptor 2\u00a0testing in breast cancer: American society of clinical oncology\/college of american pathologists clinical practice guideline focused update \u2013 PubMed [Internet]. [cited 2022\u00a0Jun 3]. Disponible \u00e0\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/29846104\/."},{"issue":"3","key":"10.1016\/j.bulcan.2023.01.013_bib0345","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2\u00a0diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"R\u00fcschoff","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0350","unstructured":"Detection of ERBB2\u00a0amplification by next-generation sequencing predicts HER2\u00a0Expression in colorectal carcinoma \u2013 PubMed [Internet]. [cited 2022\u00a0Jun 3]. Disponible \u00e0\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/31115453\/."},{"issue":"16","key":"10.1016\/j.bulcan.2023.01.013_bib0355","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of american pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.01.013_bib0360","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1158\/1078-0432.CCR-18-3389","article-title":"Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer","volume":"25","author":"Siravegna","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0365","unstructured":"Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2\u00a0in plasma circulating tumor DNA \u2013 PubMed [Internet]. [cited 2022\u00a0Jun 3]. Disponible \u00e0\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/31227437\/."},{"issue":"3","key":"10.1016\/j.bulcan.2023.01.013_bib0370","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.18632\/oncotarget.6498","article-title":"HER2\u00a0genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer","volume":"7","author":"Takegawa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0375","doi-asserted-by":"crossref","first-page":"v207","DOI":"10.1093\/annonc\/mdx393.137","article-title":"TRIUMPH Study: a multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602)","volume":"28","author":"Nakamura","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0380","unstructured":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2\u00a0trial | Nature Medicine [Internet]. [cited 2022\u00a0Jun 3]. Disponible \u00e0\u00a0: https:\/\/www.nature.com\/articles\/s41591-021-01553-w."},{"issue":"3","key":"10.1016\/j.bulcan.2023.01.013_bib0385","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cam4.228","article-title":"Comparison of HER2\u00a0expression between primary colorectal cancer and their corresponding metastases","volume":"3","author":"Lee","year":"2014","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.bulcan.2023.01.013_bib0390","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s00432-018-2744-z","article-title":"Variability in HER2\u00a0expression between primary colorectal cancer and corresponding metastases","volume":"144","author":"Shan","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.01.013_bib0395","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-16-1863","article-title":"Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer","volume":"23","author":"Pietrantonio","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bulcan.2023.01.013_bib0400","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","article-title":"Loss of HER2\u00a0positivity after anti-HER2\u00a0chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2\u00a0reassessment study 3 (GASTHER3)","volume":"22","author":"Seo","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0405","unstructured":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. [Internet]. UCSF Helen Diller family comprehensive cancer center. [cited 2022\u00a0Jun 3]. Disponible \u00e0\u00a0: https:\/\/cancer.ucsf.edu\/node\/283196."},{"key":"10.1016\/j.bulcan.2023.01.013_bib0410","unstructured":"International harmonization of provisional diagnostic criteria for ERBB2-amplified metastatic colorectal cancer allowing for screening by next-generation sequencing panel \u2013 PubMed [Internet]. [cited 2022\u00a0Jun 3]. Disponible \u00e0\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/35050726\/."},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0415","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cXenopatients\u201d) identifies HER2\u00a0as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.bulcan.2023.01.013_bib0420","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/bjc.2014.483","article-title":"HER2\/neu testing in primary colorectal carcinoma","volume":"111","author":"Ingold Heppner","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.01.013_bib0425","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/path.4679","article-title":"HER2\u00a0overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256\u00a0patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","volume":"238","author":"Richman","year":"2016","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.01.013_bib0430","first-page":"198","article-title":"Prognostic and predictive value of HER2\u00a0amplification in patients with metastatic colorectal cancer","volume":"17","author":"Sawada","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2023.01.013_bib0435","doi-asserted-by":"crossref","first-page":"e98528","DOI":"10.1371\/journal.pone.0098528","article-title":"HER2\u00a0status in colorectal cancer: its clinical significance and the relationship between HER2\u00a0gene amplification and expression","volume":"9","author":"Seo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00226","article-title":"Validation of HER2\u00a0amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer","volume":"3","author":"Raghav","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.01.013_bib0445","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","article-title":"HER2\u00a0positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer","volume":"24","author":"Sartore-Bianchi","year":"2019","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0450","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jamaoncol.2020.0571","article-title":"Central nervous system as possible site of relapse in ERBB2-positive metastatic colorectal cancer: long-term results of treatment with trastuzumab and lapatinib","volume":"6","author":"Sartore-Bianchi","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12907-019-0085-8","article-title":"Clinical significance of HER2\u00a0and EGFR expression in colorectal cancer patients with ovarian metastasis","volume":"19","author":"Li","year":"2019","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0460","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1016\/j.annonc.2021.08.960","article-title":"439P Characteristics and treatment patterns among patients with HER2-amplified advanced\/metastatic colorectal cancer (mCRC): a clinical-genomic database study","volume":"32","author":"Strickler","year":"2021","journal-title":"Ann Oncol"},{"issue":"9604","key":"10.1016\/j.bulcan.2023.01.013_bib0465","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study","volume":"370","author":"Quasar Collaborative Group","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bulcan.2023.01.013_bib0470","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","article-title":"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial","volume":"14","author":"Seymour","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9582","key":"10.1016\/j.bulcan.2023.01.013_bib0475","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2023.01.013_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-1","article-title":"Is overexpression of HER-2\u00a0a predictor of prognosis in colorectal cancer?","volume":"9","author":"Kavanagh","year":"2009","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.01.013_bib0485","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/PAS.0b013e318272ff4d","article-title":"Frequency of HER-2\u00a0positivity in rectal cancer and prognosis","volume":"37","author":"Conradi","year":"2013","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"10.1016\/j.bulcan.2023.01.013_bib0490","first-page":"113","article-title":"Prognostic value and molecular landscape of HER2\u00a0low-expressing metastatic colorectal cancer","volume":"20","author":"Yagisawa","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0495","unstructured":"Does overexpression of HER-2\u00a0correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis \u2013 PMC [Internet]. [cited 2022\u00a0Jun 9]. Disponible \u00e0\u00a0: https:\/\/www-ncbi-nlm-nih-gov.translate.goog\/pmc\/articles\/PMC4537540\/?_x_tr_sl=en&_x_tr_tl=fr&_x_tr_hl=fr&_x_tr_pto=sc."},{"key":"10.1016\/j.bulcan.2023.01.013_bib0500","unstructured":"Activation of ERBB2\u00a0signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab \u2013 PubMed [Internet]. [cited 2022\u00a0Jun 9]. Disponible \u00e0\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/21900593\/."},{"issue":"33","key":"10.1016\/j.bulcan.2023.01.013_bib0505","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.01.013_bib0510","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2\u00a0randomized clinical trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2023.01.013_bib0515","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","article-title":"HER2\u00a0activating mutations are targets for colorectal cancer treatment","volume":"5","author":"Kavuri","year":"2015","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0520","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1081\/CNV-200039645","article-title":"Low overexpression of HER-2\/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial","volume":"22","author":"Ramanathan","year":"2004","journal-title":"Cancer Invest"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0525","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13\u00a0wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2\u00a0trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.01.013_bib0530","first-page":"256","article-title":"Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer","volume":"19","author":"Tosi","year":"2020","journal-title":"Clin Colorectal Cancer"},{"issue":"3_suppl","key":"10.1016\/j.bulcan.2023.01.013_bib0535","doi-asserted-by":"crossref","first-page":"TPS153","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS153","article-title":"MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)","volume":"39","author":"Strickler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.bulcan.2023.01.013_bib0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2022.40.4_suppl.097","article-title":"Anti-HER2\u00a0therapy with pyrotinib and trastuzumab in refractory HER2-positive metastatic colorectal cancer: a preliminary report from HER2-FUSCC-G study","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0545","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.01.013_bib0550","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4_suppl","key":"10.1016\/j.bulcan.2023.01.013_bib0555","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2020.38.4_suppl.132","article-title":"Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2\u00a0amplification or overexpression: results from the TAPUR study","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0560","doi-asserted-by":"crossref","first-page":"e2200306","DOI":"10.1200\/PO.22.00306","article-title":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2\/3 Mutations: Results From the TAPUR Study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0565","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2\u00a0trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3_suppl","key":"10.1016\/j.bulcan.2023.01.013_bib0570","doi-asserted-by":"crossref","first-page":"TPS352","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS352","article-title":"A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers","volume":"39","author":"Pant","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0575","unstructured":"Zymeworks Inc. Phase I trial of ZW25\u00a0in patients with locally advanced (unresectable) and\/or metastatic HER2-expressing cancers [Internet]. clinicaltrials.gov; 2022\u00a0Feb [cited 2022\u00a0Jun 8]. Report No.: NCT02892123. Disponible \u00e0\u00a0: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02892123."},{"key":"10.1016\/j.bulcan.2023.01.013_bib0580","unstructured":"Zymeworks Inc. Phase 2\u00a0study of ZW25\u00a0plus first-line combination chemotherapy in HER2-expressing gastrointestinal (GI) cancers, including gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), and colorectal cancer (CRC) [Internet]. clinicaltrials.gov; 2022\u00a0May [cited 2022\u00a0Jun 8]. Report No.: NCT03929666. Disponible \u00e0\u00a0: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03929666."},{"key":"10.1016\/j.bulcan.2023.01.013_bib0585","unstructured":"Klus Pharma Inc. A Phase I-II, FIH study of A166\u00a0in locally advanced\/metastatic solid tumors expressing human epidermal growth factor receptor 2 (HER2) or are HER2\u00a0amplified that did not respond or stopped responding to approved therapies [Internet]. clinicaltrials.gov; 2022\u00a0Jan [cited 2022\u00a0Jun 8]. Report No.: NCT03602079. Disponible \u00e0\u00a0: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03602079."},{"key":"10.1016\/j.bulcan.2023.01.013_bib0590","doi-asserted-by":"crossref","unstructured":"Phase I study of A166\u00a0in patients with HER2-expressing locally advanced or metastatic solid tumors. | Journal of Clinical Oncology [Internet]. [cited 2022\u00a0Jun 20]. Disponible \u00e0\u00a0: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO. 2021.39.15_suppl.1024.","DOI":"10.1200\/JCO.2021.39.15_suppl.1024"},{"issue":"11","key":"10.1016\/j.bulcan.2023.01.013_bib0595","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bulcan.2023.01.013_bib0600","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-1956-3","article-title":"Molecular pathological classification of colorectal cancer","volume":"469","author":"M\u00fcller","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.bulcan.2023.01.013_bib0605","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920936089","article-title":"Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer","volume":"12","author":"Martini","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.01.013_bib0610","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2478\/raon-2020-0031","article-title":"Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision","volume":"54","author":"Rebersek","year":"2020","journal-title":"Radiol Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.01.013_bib0615","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1158\/1078-0432.CCR-17-1234","article-title":"Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies","volume":"24","author":"Sveen","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.bulcan.2023.01.013_bib0620","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11864-021-00913-5","article-title":"The evolving role of consensus molecular subtypes: a step beyond inpatient selection for treatment of colorectal cancer","volume":"22","author":"Ros","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.013_bib0625","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annpat.2021.07.014","article-title":"2021\u00a0update of the GEFPICS\u2019 recommendations for HER2\u00a0status assessment in invasive breast cancer in France","volume":"41","author":"Franchet","year":"2021","journal-title":"Ann Pathol"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2023.01.013_bib0630","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2021.39.15_suppl.3555","article-title":"Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602)","volume":"39","author":"Okamoto","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.01.013_bib0635","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.bulcan.2023.01.013_bib0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/DCR.0b013e3181c703a4","article-title":"Comparison of 17,641\u00a0patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival","volume":"53","author":"Benedix","year":"2010","journal-title":"Dis Colon Rectum"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:57Z","timestamp":1757792217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0007455123000796"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.01.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cibler HER2\u00a0dans le cancer colorectal","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}